ONTY

Current-4 months: Two compounds, PX-478 and PX-866, have promising preclinical profiles and are both in Phase I trials, with data readouts in '09. Limited number of outstanding shares and small market cap + positive data could warrant a share price increase above their 52 week high of $7.77.

Sentiment: Buy @ $5.30; Strong buy @$5.05

PJP

December 2009: stocks to watch

MSHL http://finance.yahoo.com/q?s=mshl
Price: .825 (8-13-09)
52 wk range: .25 (3-10-09) to 3.32 (8-26-08)
Upcoming event: data analysis from Phase 3 trail set for 12-17-09
Thoughts: good buy, $25 million cash, $0 debt; far enough away (as of 8-2009) to get a good rise in price (AG)

November 2009: stocks to watch

NRIFF.PK http://finance.yahoo.com/q?s=nriff.pk
Price: .24 (8-12-09)
52 wk range: .064 (11-19-08) to .429 (7-23-09)
Upcoming event: PDUFA 11-4-09
Thoughts: good buy... PDUFA delayed to new november date (AG)


XNPT http://finance.yahoo.com/q?s=xnpt
Price: 19.86 (8-12-09)
52 wk range: 13.36 (4-30-09) to 51.42 (8-15-08)
Upcoming event: PDUFA 11-09-09
Thoughts: maybe good buy (AG)


GENZ http://finance.yahoo.com/q?s=genz
Price: 50.31 (8-12-09)
52 wk range: 47.09 (8-10-09) to 83.97 (8-15-08)
Upcoming event: PDUFA 11-14-09
Thoughts: big company, at 52 wk low, after 11-14-09 PDUFA it looks like they are also going to file an amendment to their BLA with a possible additional 4 month review time (AG)


CRXX http://finance.yahoo.com/q?s=crxx
Price: 1.05 (8-12-09)
52 wk range: .25 (1-26-09) to 6.99 (9-29-08)
Upcoming event: PDUFA 11-22-09
Thoughts: good buy, way off its 52 wk high (AG)
Further analysis: CRXX merged with Neuromed (7-1-09), Neuromed has drug Exalgo (rights owned by Mallinckrodt) which is in FDA review with advisory panel 9-23-09 and PDUFA 11-22-09 http://finance.yahoo.com/news/CombinatoRx-and-Neuromed-Sign-bw-2619505124.html?x=0&.v=1

October 2009: stocks to watch

OTC.BIEL: Bioelectronics http://finance.yahoo.com/q?s=BIEL.PK

52 wk: 0.01-0.12

current: 0.076

PDUFA Date: 10/15/09

"The analyst, Carrie Snyder, places a target price on the shares of between $0.30 and $0.50, should expected FDA clearances be granted" (BH)

ACOR: Acorda Therapeutics http://finance.yahoo.com/q?s=acor

52 week: 14.42- 29.27

current: 23.77

FDA advisory committee meeting: 10-14-09

PDUFA: 10-22-09

September 2009: stocks to watch

CRXX: advisory panel 9-23-09; (see Nov. for PDUFA details)

ACHN http://finance.yahoo.com/q?s=achn
Price: 1.99 (8-11-09)
52 wk range: .65 (12-31-08) to 3.00 (8-21-08)
Upcoming event: safety and tolerability data for Phase I HCV trail (late summer); efficacy data (winter 09)
Thoughts: Phase I too early, not a good buy (AG)


PARS.PK http://finance.yahoo.com/q?s=PARS.PK
Price: .46 (8-11-09)
52 wk range: .02 (3-20-09) to .48 (8-11-09)
Upcoming event: Results from Phase IIb trial expected Sept. 09
Thoughts: maybe good buy; already missed out on 2,000% in the last 3 months (AG)


ENDP http://finance.yahoo.com/q?s=endp
Price: 21.06 (8-11-09)
52 wk range: 13.87 (10-10-08) to 26.14 (1-2-09)
Upcoming event: PDUFA 9-2-09
Thoughts: too big (AG)


SLXP http://finance.yahoo.com/q?s=slxp
Price: 12.54 (8-11-09)
52 wk range: 5.07 (10-10-08) to 13.26 (7-26-09)
Upcoming event : PDUFA 9-11-09
Thoughts: too late? (AG)

Welcome to BiotechDayTrader

I thought this might be a good format for us be able to put our biotech stock analysis in one place for everyone to be able to refer back to.